EUVIMED · CrossrefJournal
Expert Opinion on Therapeutic Patents
ISSN 1354-3776 · Informa Healthcare
Latest articles
A patent review of GDF15 inhibitors 2020-present
Therapeutic potential of glycyrrhetinic acids: an updated patent review (2018–2024)
A patent review of anti‑VEGF antibodies for the treatment of ocular diseases (2020–present)
Allosteric anticoagulation: emerging non-orthosteric inhibitors of factor XI and factor XIa
Overcoming the blood–brain barrier for therapeutics targeting neurodegenerative diseases: a patent review (2020–present)
Global patent landscape of synthetic drugs for melasma (2015–2025): innovation trends, mechanistic shifts, and translational challenges
Aurora kinase inhibitors: an updated patent review (2021–present)
Progress with FAK inhibitors in the patent literature (2020-present)
Selective PARP1 inhibitors (2021–2025): patent landscape, structural evolution, and future therapeutic opportunities
A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021–2025)
A patent perspective of RSK inhibitors to treat cancer (2020-present)
SLIT2 and ROBO-axis inhibitors for the treatment of cancer: a patent review (2020–2026)
A patent review of GPR84 receptor antagonists (2020–present)
An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020–present)
AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review (2020–present)
Recent patent landscape of ASK1 inhibitors: spotlight on 2-(1-isopropyl-4H-1,2,4-triazole-3-yl) pyridine as a privileged scaffold
An updated patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2020–2025)
An update on PDGFR inhibitors: a patent review (2020 - present)
Takeda G-protein-coupled receptor 5 and farnesoid X receptor agonists for diabetes treatment: a patent review and clinical advancements (2015-present)
New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present)
Small molecule agonists of Toll-like receptors 7 and 8: an updated patent review 2021 – 2025
A patent review of LPAR1 antagonists (2010 – present)
Recent advances in the discovery of PKMYT1-targeting drugs: a patent review (2021–2025)
PCSK9 inhibitors: an updated patent review 2024–2025
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes
Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present)
5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present)
An updated patent review of isoflavones and isocoumarins (2018–2024)
An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease (2021–present)
Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with in vitro activity against Acinetobacter baumannii : a patent evaluation (US 2025/0223303)
Volumes
2026 · 592025 · 682024 · 692023 · 522022 · 662021 · 712020 · 722019 · 742018 · 772017 · 1042016 · 1102015 · 1222014 · 1142013 · 1242012 · 1002011 · 1122010 · 1192009 · 1212008 · 1042007 · 1122006 · 1172005 · 1202004 · 1702003 · 2492002 · 1322001 · 1262000 · 1491999 · 1381998 · 1331997 · 1221996 · 1411995 · 1301994 · 230
EUVIMED